Fei Yu

Dr. Fei Yu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YMYingying Mao
Yingying Mao
WYWenjun Yang
Wenjun Yang
QQQi Qi
Qi Qi
FYFei Yu
Fei Yu
TWTianpei Wang
Tianpei Wang
Guangfu JinGuangfu Jin
Guangfu Jin
The association of ABO blood groups with gastric cancer risk was proposed decades ago, but the results have been inconsistent. We used two single nucleotide polymorphisms to determine ABO genotype in 4932 gastric cancer cases and 6158 controls of Chinese descent, and evaluated the associations of ABO blood groups and genotypes with risk of gastric cancer using multivariable logistic regression models. We also systematically reviewed published literature and performed a meta-analysis of all relevant studies. In the case-control study, compared with blood group O, both blood group A and AB were associated with increased gastric cancer risk (for group A, odds ratio (OR) = 1.13, 95% confidence interval (CI): 1.02–1.24; for group AB, OR = 1.18, 95% CI: 1.02–1.36, respectively). Analyses of ABO genotypes revealed associations of AO and AB with risk of gastric cancer compared with OO genotype. Consistent with the case-control study, meta-analysis of 40 studies including 33,613 cases and 2,431,327 controls demonstrated that blood group A (OR = 1.19, 95% CI: 1.13–1.25) and AB (OR = 1.09, 95% CI: 1.03–1.16) were associated with increased risk of gastric cancer. Our analyses validated the association of blood group A with risk of gastric cancer, and suggested that blood group AB was also associated with gastric cancer risk. Functional investigations are warranted to elucidate the exact mechanism of ABO blood groups in gastric carcinogenesis.

2 October 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MHMarina Hodolic
Marina Hodolic
WWWen-Yu Wu
Wen-Yu Wu
ZZZhenyu Zhao
Zhenyu Zhao
FYFei Yu
Fei Yu
IVIrene Johanna Virgolini
Irene Johanna Virgolini
FWFeng Wang
Feng Wang

7 November 2022 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
RTRui Tian
Rui Tian
QXQing Xie
Qing Xie
FYFei Yu
Fei Yu
CDChangzhi Du
Changzhi Du
XYXiaochen Yao
Xiaochen Yao
JYJiangyuan Yu
Jiangyuan Yu
Purpose. This study aimed to assess the efficacy of dual‐tracer [68Ga‐DOTA‐somatostatin receptor analogs (SSAs) and 18F‐fluorodeoxyglucose (FDG)] positron emission tomography/computed tomography (PET/CT) imaging for detecting bone metastases (BMs) in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs). Methods. We retrospectively enrolled 74 GEP‐NEN patients with BMs from two centers, who underwent dual‐tracer PET/CT from January 2014 to March 2021. We compared and analyzed effectiveness of the dual PET/CT imaging techniques on the BMs, based on 18F‐FDG and 68Ga‐DOTA‐SSAs. Specifically, we analyzed the imaging results using χ2 tests for classification variables, paired‐sample tests for number of BMs, Wilcoxon’s signed rank test for number of lesions, and the Kruskal–Wallis test for standard uptake value (SUV) ratio comparison. The correlation of dual‐tracer SUVmax with Ki‐67 index was analyzed by Spearman’s correlation coefficient. Results. The detection efficiencies of dual‐tracer PET/CT imaging in patients with different pathologies showed discordant for detecting liver metastases and BMs in group neuroendocrine tumor (NET) G3, 68Ga‐DOTA‐SSAs was better at detecting BMs for NET G3 (P = 0.049 for SUVT/B and P = 0.026 for the number of metastatic lesions). In addition, statistical significance was found among osteogenesis group, osteolysis group, and the no‐change group (for bone SUVT/B value detected by 18F‐FDG and Ki‐67 index, osteogenesis group < osteolysis group; for bone SUVT/B detected by 68Ga‐DOTA‐SSAs, osteogenesis group > the no‐change group). What is more, liver and bone SUVmax and Ki‐67 index were positively correlated in 18F‐FDG imaging (P < 0.001 for liver; P = 0.002 for bone), and negatively correlated in 68Ga‐DOTA‐SSAs imaging (P < 0.001 for liver; P = 0.039 for bone). Conclusions. 68Ga‐DOTA‐SSAs was superior to 18F‐FDG for detecting BMs in NET G1/G2 (well and moderately differentiated NETs), as well as in NET G3 (poorly differentiated NETs). Relatively good differentiation was observed in the osteogenesis group. In addition, dual‐tracer PET/CT imaging results were observably correlated with tumor differentiation.

20 March 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
LSLiang Shi
Liang Shi
MGMuhong Guo
Muhong Guo
CSCuixiao Shi
Cuixiao Shi
GGGu Gao
Gu Gao
XXXianghong Xu
Xianghong Xu
FYFei Yu
Fei Yu
Purpose: Trimethylamine N-oxide (TMAO), a gut microbiome–derived metabolite, and its precursors (carnitine, choline, betaine) have not been fully examined in relation to thyroid cancer (TC) risk. The aim of this study was to assess the value of TMAO and its precursors in diagnosis of benign and malignant thyroid nodules. Methods: In this study, high-performance liquid chromatography-tandem mass spectrometry was utilized to measure the levels of plasma TMAO and its precursors (choline, carnitine, and betaine) in 215 TC patients, 63 benign thyroid nodules (BTN) patients and 148 healthy controls (HC). The distribution of levels of TMAO and its precursors among the three groups were compared by the Kruskal–Wallis test. Receiver operating characteristic curve (ROC) analysis was performed to evaluate the sensitivity, specificity, and the predictive accuracy of single and combined biomarkers. Results: In comparison to HC, TC showed higher levels of TMAO and lower levels of its precursors (carnitine, choline, and betaine) (all P < 0.001). Plasma choline (P < 0.01) and betaine (P < 0.05) were declined in BTN than HC. The levels of carnitine (P < 0.001) and choline (P < 0.05) were significantly higher in BTN than that in TC group. Plasma TMAO showed lower levels in TC with lymph node metastasis (101.5 (73.1–144.5) ng/ml) than those without lymph node metastasis (131 (84.8–201) ng/ml, P < 0.05). Combinations of these four metabolites achieved good performance in the differential diagnosis, with the area under the ROC curve of 0.703, 0.741, 0.793 when discriminating between TC and BTN, BTN and HC, TC and HC, respectively. Conclusion: Plasma TMAO, along with its precursors could serve as new biomarkers for the diagnosis of benign and malignant thyroid nodules.

1 January 2026 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
FYFei Yu
Fei Yu
JPJingya Pan
Jingya Pan
LZLiuting Zhang
Liuting Zhang
SLShaohua Li
Shaohua Li
CZChuan Zhang
Chuan Zhang
LSLiang Shi
Liang Shi
Objective: Accurate assessment of metastatic status is crucial for determining radioactive iodine (RAI) dosing in postoperative papillary thyroid carcinoma (PTC) patients. This study aimed to identify unbiased biomarkers in metastatic PTC patients after surgery by applying a metabolomics workflow in saliva samples. Materials and methods: Saliva samples from 70 postoperative PTC patients (35 metastatic PTC patients in metastasis group and 35 non-metastatic PTC patients in control group) were analyzed using liquid chromatography – mass spectrometry. Orthogonal partial least-squares-discriminant analysis [...] ABSTRACT Objective: Accurate assessment of metastatic status is crucial for determining radioactive iodine (RAI) dosing in postoperative papillary thyroid carcinoma (PTC) patients. This study aimed to identify unbiased biomarkers in metastatic PTC patients after surgery by applying a metabolomics workflow in saliva samples. Materials and methods: Saliva samples from 70 postoperative PTC patients (35 metastatic PTC patients in metastasis group and 35 non-metastatic PTC patients in control group) were analyzed using liquid chromatography – mass spectrometry. Orthogonal partial least-squares-discriminant analysis